Salud financiera de hoja de balance de Lantern Pharma
Salud financiera controles de criterios 6/6
Lantern Pharma tiene un patrimonio de los accionistas total de $26.6M y una deuda total de $0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son $30.3M y $3.7M respectivamente.
Información clave
0%
Ratio deuda-patrimonio
US$0
Deuda
| Ratio de cobertura de intereses | n/a |
| Efectivo | US$28.05m |
| Patrimonio | US$26.60m |
| Total pasivo | US$3.70m |
| Activos totales | US$30.29m |
Actualizaciones recientes sobre salud financiera
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Nov 05
Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Recent updates
Is Lantern Pharma (NASDAQ:LTRN) In A Good Position To Invest In Growth?
Nov 05Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jun 12We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Feb 28We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
Nov 06Lantern Pharma (NASDAQ:LTRN) Is In A Good Position To Deliver On Growth Plans
Jul 20We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Apr 04Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Dec 19We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Sep 02Lantern Pharma gets FDA nod to start mid-stage study of LP-300 in lung cancer
Jul 14Companies Like Lantern Pharma (NASDAQ:LTRN) Are In A Position To Invest In Growth
May 20Here's Why We're Not Too Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Situation
Feb 02We're Hopeful That Lantern Pharma (NASDAQ:LTRN) Will Use Its Cash Wisely
Oct 13Lantern Pharma: Consider A Speculative Long-Term Investment In This AI Drug Discoverer
Aug 24Lantern Pharma: Drug Recycling With AI
Jun 08We're Not Very Worried About Lantern Pharma's (NASDAQ:LTRN) Cash Burn Rate
May 05Lantern Pharma reports Q1 results
May 03Here's What Lantern Pharma Inc.'s (NASDAQ:LTRN) Shareholder Ownership Structure Looks Like
Feb 19
Lantern Pharma announces antibody drug conjugate tie-up with Califia Pharma
Jan 04Who Has Been Buying Lantern Pharma Inc. (NASDAQ:LTRN) Shares?
Dec 28Lantern: Early Stage 'Smart Drug' Discovery Company
Nov 25Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo ($29.9M) de LTRN superan a sus pasivos a corto plazo ($3.6M).
Pasivo a largo plazo: Los activos a corto plazo de LTRN ($29.9M) superan a sus pasivos a largo plazo ($94.0K).
Historial y análisis de deuda-patrimonio
Nivel de deuda: LTRN está libre de deudas.
Reducción de la deuda: LTRN no tenía deudas hace 5 años.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: LTRN tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.
Pronóstico de cash runway: LTRN dispone de suficiente cash runway para 1.4 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 30% cada año.